Not Signed In -
Sildenafil |
sildenafil citrate; Viagra |
Clinical Trial: Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension
This study is currently recruiting patients.
Verified by National Taiwan University Hospital June 2005
|
Purpose
The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors (sildenafil) in primary and secondary pulmonary hypertension
| Condition | Intervention |
|---|---|
| primary and secondary pulmonary hypertension | Drug: type-5 phosphodiesterase Inhibitor (Sildenafil) |
MedlinePlus related topics: Pulmonary Hypertension
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Official Title: Clinical Efficacy of Type-5 Phosphodiesterase Inhibitors (Sildenafil and Vadenafil) in Primary and Secondary Pulmonary Hypertension
Further Study Details:
Primary Outcomes: mean pulmonary artery pressure; 6 min walking distance; WHO functional status; PaO2
Secondary Outcomes: cardiac output; VO2max
Expected Total Enrollment: 20
Secondary Outcomes: cardiac output; VO2max
Expected Total Enrollment: 20
Study start: November 2002; Expected completion: December 2005
Last follow-up: May 2005; Data entry closure: November 2005
Patients with primary and secondary pulmonary hypertension will be recruited and admitted to the ICUs of the National Taiwan University Hospital. Each patient will undergo Swan-Ganz catheterization and hemodynamic monitoring during administration of sildenafil. Efficacy of inhaled NO and Iloprost will also be compared.
Eligibility
Ages Eligible for Study: 12 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:Patients with primary and secondary pulmonary arterial hypertension
-
Exclusion Criteria:Unstable patients or patients with allergy to sildenafil
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00155714
Ping-Hung Kuo, MD 886-2-23123456 Ext. 3075 kph@ntumc.org
Ping-Hung Kuo, MD
Ping-Hung Kuo, MD
Taiwan
Ping-Hung Kuo, Taipei, 100, Taiwan; Recruiting
Ping-Hung Kuo, MD
Ping-Hung Kuo, MD, Principal Investigator
Ping-Hung Kuo, MD, Principal Investigator
Study chairs or principal investigators
Ping-Hung Kuo, MD, Principal Investigator, National Taiwan University Hospital
More Information
Study ID Numbers: 9100017321
Last Updated: September 9, 2005
Record first received: September 9, 2005
ClinicalTrials.gov Identifier: NCT00155714
Health Authority: Taiwan: Department of Health
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 9, 2005
Record first received: September 9, 2005
ClinicalTrials.gov Identifier: NCT00155714
Health Authority: Taiwan: Department of Health
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Sildenafil (Drug Digest)
- Viagra (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
